Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
Andrea AntinoriStefania CicaliniSilvia MeschiVeronica BordoniPatrizia LorenziniAlessandra VergoriSimone LaniniLidya De PascaleGiulia MatusaliDavide MariottiAlessandro Cozzi LepriPaola GallìCarmela PinnettiRoberta GagliardiniValentina MazzottaIlaria MastrorosaSusanna GrisettiFrancesca ColavitaEleonora CiminiElisabetta GrilliRita BellagambaDaniele LapaAlessandra SacchiAlessandra MaraniCarlo CeriniCaterina CandelaMarisa FustoVincenzo PuroConcetta CastillettiChiara AgratiEnrico GirardiFrancesco Vaianull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm3 versus those with >500 cell/mm3 and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200-500/mm3, whereas immune response elicited in PLWH with a CD4 T-cell >500/mm3 was comparable to HIV-negative population.
Keyphrases
- immune response
- antiretroviral therapy
- human immunodeficiency virus
- sars cov
- respiratory syndrome coronavirus
- hiv infected
- hiv positive
- hiv aids
- hepatitis c virus
- hiv infected patients
- dendritic cells
- single cell
- toll like receptor
- coronavirus disease
- peripheral blood
- cell therapy
- hiv testing
- binding protein
- inflammatory response
- men who have sex with men
- stem cells
- south africa
- dna binding